![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M Jurima-Romet, K Crawford, T Cyr and T Inaba
Bureau of Drug Research, Health Canada, Ottawa.
To determine whether the clinical adverse interactions of terfenadine with azole antifungals and macrolide antibiotics may be related to inhibition of terfenadine biotransformation, an in vitro system was developed to follow the metabolism of terfenadine by rat liver S9 or human liver microsomes. When test compounds were coincubated with terfenadine, the metabolites formed and unchanged terfenadine was quantitatively analyzed by HPLC. Five metabolites of terfenadine were formed by rat liver S9: predominantly alcohol metabolite (III), with four minor metabolites--azacyclonol (I), acid metabolite (II), an unidentified metabolite (IV), and a new ketone metabolite (V). By human liver microsomes, two major metabolites were formed: azacyclonol (I) and alcohol metabolite (III). Ketoconazole, fluconazole, itraconazole, erythromycin, clarithromycin, and troleandomycin potently inhibited terfenadine metabolism by human liver (IC50 = 4-10 microM), but inhibition by rat liver was weaker (IC50 = 87-218 microM) and 18% maximally for troleandomycin. Other CYP3A substrates (cyclosporin A, naringenin, and midazolam) also demonstrated potent inhibition of terfenadine biotransformation in human liver microsomes (IC50 = 17-24 microM). Substrates of other P450 families [sparteine (CYP2D6), caffeine (CYP1A), and diclofenac (CYP2C)] only very weakly inhibited terfenadine metabolism. Dixon plot analyses for human liver revealed competitive/reversible inhibition by the azole antifungals and macrolide antibiotics of azacyclonol and alcohol metabolite formations.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  P. J. Murphy The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 3, 1984-2008 Drug Metab. Dispos., October 1, 2008; 36(10): 1977 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Yoo, H. J. Chung, J. Lee, C.-S. Lee, M. J. Kang, and D.-H. Kim Enzymatic C-Demethylation of 1-[2-(5-tert-Butyl-[1,3,4] oxadiazole-2-carbonyl)-4-fluoro-pyrrolidin-1-yl]-2-(2-hydroxy-1,1-dimethyl-ethylamino)-ethanone (LC15-0133) in Rat Liver Microsomes Drug Metab. Dispos., March 1, 2008; 36(3): 485 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sudsakorn, J. Skell, D. A. Williams, T. J. O'Shea, and H. Liu Evaluation of 3-O-Methylfluorescein as a Selective Fluorometric Substrate for CYP2C19 in Human Liver Microsomes Drug Metab. Dispos., June 1, 2007; 35(6): 841 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Z. Turncliff, K. A. Hoffmaster, J. C. Kalvass, G. M. Pollack, and K. L. R. Brouwer Hepatobiliary Disposition of a Drug/Metabolite Pair: Comprehensive Pharmacokinetic Modeling in Sandwich-Cultured Rat Hepatocytes J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 881 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Iwata, Y. Tezuka, S. Kadota, A. Hiratsuka, and T. Watabe IDENTIFICATION AND CHARACTERIZATION OF POTENT CYP3A4 INHIBITORS IN SCHISANDRA FRUIT EXTRACT Drug Metab. Dispos., December 1, 2004; 32(12): 1351 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zhou, E. Chan, S.-Q. Pan, M. Huang, and E. J. D. Lee Pharmacokinetic Interactions of Drugs with St John's Wort J Psychopharmacol, June 1, 2004; 18(2): 262 - 276. [Abstract] [PDF]
|
|
|
|
|
|
K. Ito, K. Ogihara, S.-i. Kanamitsu, and T. Itoh PREDICTION OF THE IN VIVO INTERACTION BETWEEN MIDAZOLAM AND MACROLIDES BASED ON IN VITRO STUDIES USING HUMAN LIVER MICROSOMES Drug Metab. Dispos., July 1, 2003; 31(7): 945 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hashizume, S. Imaoka, M. Mise, Y. Terauchi, T. Fujii, H. Miyazaki, T. Kamataki, and Y. Funae Involvement of CYP2J2 and CYP4F12 in the Metabolism of Ebastine in Human Intestinal Microsomes J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 298 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Bruce, S. D. Hall, B. D. Haehner-Daniels, and J. C. Gorski In Vivo Effect of Clarithromycin on Multiple Cytochrome P450s Drug Metab. Dispos., July 1, 2001; 29(7): 1023 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Mayhew, D. R. Jones, and S. D. Hall An In Vitro Model for Predicting In Vivo Inhibition of Cytochrome P450 3A4 by Metabolic Intermediate Complex Formation Drug Metab. Dispos., September 1, 2000; 28(9): 1031 - 1037. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ludwig, J. Schmid, K. Beschke, and T. Ebner Activation of Human Cytochrome P-450 3A4-Catalyzed Meloxicam 5'-Methylhydroxylation by Quinidine and Hydroquinidine In Vitro J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 1 - 8. [Abstract] [Full Text]
|
|
|
|
|
|
S. M. Yule, D. Walker, M. Cole, L. McSorley, S. Cholerton, A. K. Daly, A.D.J. Pearson, and A. V. Boddy The Effect of Fluconazole on Cyclophosphamide Metabolism in Children Drug Metab. Dispos., March 1, 1999; 27(3): 417 - 421. [Abstract] [Full Text]
|
|
|
|
|
|
B. C. Jones, R. Hyland, M. Ackland, C. A. Tyman, and D. A. Smith Interaction of Terfenadine and Its Primary Metabolites with Cytochrome P450 2D6 Drug Metab. Dispos., September 1, 1998; 26(9): 875 - 882. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Ito, T. Iwatsubo, S. Kanamitsu, K. Ueda, H. Suzuki, and Y. Sugiyama Prediction of Pharmacokinetic Alterations Caused by Drug-Drug Interactions: Metabolic Interaction in the Liver Pharmacol. Rev., September 1, 1998; 50(3): 387 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dumaine, M.-L. Roy, and A. M. Brown Blockade of HERG and Kv1.5 by Ketoconazole J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 727 - 735. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Lillibridge, B. H. Liang, B. M. Kerr, S. Webber, B. Quart, B. V. Shetty, and C. A. Lee Characterization of the Selectivity and Mechanism of Human Cytochrome P450 Inhibition by the Human Immunodeficiency Virus-Protease Inhibitor Nelfinavir Mesylate Drug Metab. Dispos., July 1, 1998; 26(7): 609 - 616. [Abstract] [Full Text]
|
|
|
|
|
|
T. Hashizume, M. Mise, Y. Terauchi, L. O, T. Fujii, H. Miyazaki, and T. Inaba N-Dealkylation and Hydroxylation of Ebastine by Human Liver Cytochrome P450 Drug Metab. Dispos., June 1, 1998; 26(6): 566 - 571. [Abstract] [Full Text]
|
|
|
|
|
|
A. J. Draper, A. Madan, K. Smith, and A. Parkinson Development of a Non-High Pressure Liquid Chromatography Assay to Determine Testosterone Hydroxylase (CYP3A) Activity in Human Liver Microsomes Drug Metab. Dispos., April 1, 1998; 26(4): 299 - 304. [Abstract] [Full Text]
|
|
|
|
|
|
S. Takedomi, H. Matsuo, K. Yamano, K. Yamamoto, T. Iga, and Y. Sawada Quantitative Prediction of the Interaction of Midazolam and Histamine H2 Receptor Antagonists in Rats Drug Metab. Dispos., April 1, 1998; 26(4): 318 - 323. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Hafner, J. Bethel, M. Power, B. Landry, M. Banach, L. Mole, H. C. Standiford, S. Follansbee, P. Kumar, R. Raasch, et al. Tolerance and Pharmacokinetic Interactions of Rifabutin and Clarithromycin in Human Immunodeficiency Virus-Infected Volunteers Antimicrob. Agents Chemother., March 1, 1998; 42(3): 631 - 639. [Abstract] [Full Text]
|
|
|
|
|
|
A. Cato III, G. Cao, A. Hsu, J. Cavanaugh, J. Leonard, and R. Granneman Evaluation of the Effect of Fluconazole on the Pharmacokinetics of Ritonavir Drug Metab. Dispos., September 1, 1997; 25(9): 1104 - 1106. [Abstract] [Full Text]
|
|
|
|
|
|
S. W. Grimm and M. C. Dyroff Inhibition of Human Drug Metabolizing Cytochromes P450 by Anastrozole, a Potent and Selective Inhibitor of Aromatase Drug Metab. Dispos., May 1, 1997; 25(5): 598 - 602. [Abstract] [Full Text]
|
|
|
|
|
|
M. E. Fitzsimmons and J. M. Collins Selective Biotransformation of the Human Immunodeficiency Virus Protease Inhibitor Saquinavir by Human Small-Intestinal Cytochrome P4503A4. Potential Contribution to High First-Pass Metabolism Drug Metab. Dispos., February 1, 1997; 25(2): 256 - 266. [Abstract] [Full Text]
|
|
|
|
 |
|
 M.-L. Roy, R. Dumaine, and A. M. Brown HERG, a Primary Human Ventricular Target of the Nonsedating Antihistamine Terfenadine Circulation, August 15, 1996; 94(4): 817 - 823. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
